LY3130481 is an AMPA receptor antagonist. It is dependent upon transmembrane AMPA receptor regulatory protein (TARP) γ-8 and selectively inhibits AMPA/TARP γ-8 (IC50: 65 nM).
(R)-Posenacaftor ((R)-PTI-801) sodium, the R enantiomer of Posenacaftor, is a cystic fibrosis transmembrane regulator (CFTR) protein modulator. It corrects the folding and trafficking of the CFTR protein, and is utilized in the research of cystic fibrosis (CF)[1].
Posenacaftor (PTI-801) sodium, a cystic fibrosis transmembrane regulator (CFTR) modulator, corrects CFTR protein folding and trafficking. It is utilized in researching cystic fibrosis (CF)[1].
The biological effects of prostaglandin D2 (PGD2) are transduced by at least two 7-transmembrane G protein-coupled receptors, designated DP1 and CRTH2/DP2. In humans, CRTH2/DP2 is expressed on Th2 cells, eosinophils, and basophils where it mediates the chemotactic activity of PGD2. CAY10597, as a racemic mixture, is a potent CRTH2/DP2 receptor antagonist that binds to the human receptor with a Ki value of 37 nM. The R enantiomer is slightly more potent exhibiting Ki values of 23 and 22 nM at the human and murine CRTH2/DP2 receptor, respectively. The R enantiomer of CAY10597 inhibits eosinophil chemotaxis induced by 13,14-dihydro-15-keto-prostaglandin D2 with an IC50 value of 40 nM.
KSPWFTTL is an immunodominant epitope derived from the p15E transmembrane protein. It is Kb-restricted and can enhance the susceptibility of a tumor cell line to cytotoxic T lymphocytes targeting anti-AKR/Gross MuLV.